A pharmaceutical composition and use thereof for relieving progression of chronic kidney disease or preventing thereof

Category: *Precision Health & Smart Medical

Exhibitor: NATIONAL DEFENSE MEDICAL CENTER

Booth No: N529

Characteristic

Chronic Kidney Disease (CKD), also known as chronic renal disease, is progressively becoming a common ailment worldwide. We have successfully established a novel, internationalized platform targeting NLRP3 inflammasome for drug development for CKD. We demonstrated that NSC828779 can: [1] enhance autophagy-mediated inhibition of the NLRP3 inflammasome; [2] suppress NF-κB/NLRP3 inflammasome axis; [3] inhibit the IL-36α signaling on renal fibrosis in a mouse renal fibrosis model. Importantly, our team also owned: [1] three approved material patents; [2] two indication patents (Approved Taiwan patent, TWI821836; US provisional patent 17/308,679, under review); [3] technology transfer to Encommelt Medical Sciences llc. Therefore, this new compound – NSC828779 may be efficacious for CKD involving excessive NLRP3 inflammasome activation and as a promising drug candidate to treat renal fibrosis.